Checkerspot and Huvepharma Partner to Commercialize Groundbreaking Human Milk Fat Analog
Clearing a Major Technological Hurdle, Checkerspot & Huvepharma Ready to Scale Production…
Roche enters into a definitive merger agreement to acquire 89bio, and its phase 3 FGF21 analog for the therapy of moderate to severe MASH
89bio’s pegozafermin allows for a potentially best-in-disease treatment for moderate to severe…
Synopsys Receives Frost & Sullivan’s 2025 Global Technology Innovation Leadership Award for Advancing Analog In-Memory Computing
Synopsys recognized for its comprehensive AI-driven EDA suite and cloud-enabled design environment…
